Treatment selection after imatinib resistance in chronic myeloid leukemia

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalReview article

Abstract

Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood. The harbinger of CML is a chromosomal translocation that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase. The advent of imatinib, an inhibitor targeted specifically for BCR-ABL, represented a significant medical advance in CML therapy. However, patients with CML can exhibit varying responses to first-line treatment with imatinib. While most patients respond to treatment, some may experience a loss of response or require treatment discontinuation due to toxicity. Frequent monitoring for resistance or intolerance is a requirement for recognition of suboptimal response. Mutational analysis of the patient's BCR-ABL alleles is also informative and may be predictive of a response to therapy. Published physician guidelines have highlighted these recommendations, but it is not clear if these guidelines are universally followed. One option in patients showing poor response to standard-dose imatinib of 400 mg is to escalate the dose. However, this option should be reserved for patients with minimal disease burden. Clinically available options mainly include second-generation tyrosine kinase inhibitors, such as dasatinib and nilotinib. Allogenic stem cell transplantations (for eligible patients) also should be considered. The disease and patient characteristics at the time of imatinib failure should be evaluated before choosing second-line therapy to optimize the therapeutic benefit without unnecessary delay.

Original languageEnglish (US)
Pages (from-to)3-10
Number of pages8
JournalTargeted Oncology
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics
Guidelines
Genetic Translocation
Stem Cell Transplantation
Imatinib Mesylate
Alleles
Physicians
Neoplasms
Proteins

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • Imatinib
  • Second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Treatment selection after imatinib resistance in chronic myeloid leukemia. / Jabbour, Elias; Cortes, Jorge; Kantarjian, Hagop.

In: Targeted Oncology, Vol. 4, No. 1, 01.01.2009, p. 3-10.

Research output: Contribution to journalReview article

Jabbour, Elias ; Cortes, Jorge ; Kantarjian, Hagop. / Treatment selection after imatinib resistance in chronic myeloid leukemia. In: Targeted Oncology. 2009 ; Vol. 4, No. 1. pp. 3-10.
@article{f910bb1b56ad476e9010ef075d264ed0,
title = "Treatment selection after imatinib resistance in chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood. The harbinger of CML is a chromosomal translocation that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase. The advent of imatinib, an inhibitor targeted specifically for BCR-ABL, represented a significant medical advance in CML therapy. However, patients with CML can exhibit varying responses to first-line treatment with imatinib. While most patients respond to treatment, some may experience a loss of response or require treatment discontinuation due to toxicity. Frequent monitoring for resistance or intolerance is a requirement for recognition of suboptimal response. Mutational analysis of the patient's BCR-ABL alleles is also informative and may be predictive of a response to therapy. Published physician guidelines have highlighted these recommendations, but it is not clear if these guidelines are universally followed. One option in patients showing poor response to standard-dose imatinib of 400 mg is to escalate the dose. However, this option should be reserved for patients with minimal disease burden. Clinically available options mainly include second-generation tyrosine kinase inhibitors, such as dasatinib and nilotinib. Allogenic stem cell transplantations (for eligible patients) also should be considered. The disease and patient characteristics at the time of imatinib failure should be evaluated before choosing second-line therapy to optimize the therapeutic benefit without unnecessary delay.",
keywords = "Chronic myeloid leukemia, Dasatinib, Imatinib, Second-line therapy",
author = "Elias Jabbour and Jorge Cortes and Hagop Kantarjian",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s11523-008-0100-y",
language = "English (US)",
volume = "4",
pages = "3--10",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "1",

}

TY - JOUR

T1 - Treatment selection after imatinib resistance in chronic myeloid leukemia

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood. The harbinger of CML is a chromosomal translocation that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase. The advent of imatinib, an inhibitor targeted specifically for BCR-ABL, represented a significant medical advance in CML therapy. However, patients with CML can exhibit varying responses to first-line treatment with imatinib. While most patients respond to treatment, some may experience a loss of response or require treatment discontinuation due to toxicity. Frequent monitoring for resistance or intolerance is a requirement for recognition of suboptimal response. Mutational analysis of the patient's BCR-ABL alleles is also informative and may be predictive of a response to therapy. Published physician guidelines have highlighted these recommendations, but it is not clear if these guidelines are universally followed. One option in patients showing poor response to standard-dose imatinib of 400 mg is to escalate the dose. However, this option should be reserved for patients with minimal disease burden. Clinically available options mainly include second-generation tyrosine kinase inhibitors, such as dasatinib and nilotinib. Allogenic stem cell transplantations (for eligible patients) also should be considered. The disease and patient characteristics at the time of imatinib failure should be evaluated before choosing second-line therapy to optimize the therapeutic benefit without unnecessary delay.

AB - Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood. The harbinger of CML is a chromosomal translocation that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase. The advent of imatinib, an inhibitor targeted specifically for BCR-ABL, represented a significant medical advance in CML therapy. However, patients with CML can exhibit varying responses to first-line treatment with imatinib. While most patients respond to treatment, some may experience a loss of response or require treatment discontinuation due to toxicity. Frequent monitoring for resistance or intolerance is a requirement for recognition of suboptimal response. Mutational analysis of the patient's BCR-ABL alleles is also informative and may be predictive of a response to therapy. Published physician guidelines have highlighted these recommendations, but it is not clear if these guidelines are universally followed. One option in patients showing poor response to standard-dose imatinib of 400 mg is to escalate the dose. However, this option should be reserved for patients with minimal disease burden. Clinically available options mainly include second-generation tyrosine kinase inhibitors, such as dasatinib and nilotinib. Allogenic stem cell transplantations (for eligible patients) also should be considered. The disease and patient characteristics at the time of imatinib failure should be evaluated before choosing second-line therapy to optimize the therapeutic benefit without unnecessary delay.

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Imatinib

KW - Second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=67349179696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349179696&partnerID=8YFLogxK

U2 - 10.1007/s11523-008-0100-y

DO - 10.1007/s11523-008-0100-y

M3 - Review article

C2 - 19343297

AN - SCOPUS:67349179696

VL - 4

SP - 3

EP - 10

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 1

ER -